Supreme Court Puts Brakes on Abortion Pill Restrictions

Follow Drugslib on

By Carmen Pope, Senior Editor, Drugs.com

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 5, 2026.

via HealthDay

MONDAY, May 4, 2026 — The Supreme Court has temporarily stepped in to preserve nationwide access to the abortion pill mifepristone, halting a lower court ruling that would have made the medication significantly harder to obtain.

Justice Samuel Alito issued the temporary pause on Monday, keeping a recent appeals court decision on hold until at least May 11. The move buys time for the Supreme Court to weigh emergency requests from mifepristone manufacturers Danco and GenBioPro while the broader legal battle plays out.

What changed, and what it means for patients

For now, mifepristone can continue to be prescribed without an in-person doctor's visit, meaning it can be mailed to patients anywhere in the country, including in states with strict abortion restrictions. That access had been thrown into uncertainty after a New Orleans appeals court sided with Louisiana's request to reinstate an older requirement that patients meet with a doctor face-to-face before receiving the drug.

Planned Parenthood Action Fund president Alexis McGill Johnson welcomed the Supreme Court's intervention, but noted that the rapid back-and-forth had already taken a toll. She said the instability had created real consequences for patients and healthcare providers trying to navigate the shifting legal landscape.

Background

The case centres on Covid-era rules made permanent by the Biden administration that allowed mifepristone to be dispensed without an in-person visit. Anti-abortion groups argue those rules should never have been made permanent. At the same time, the drug's manufacturers contend that Louisiana lacks the legal standing to challenge them. The same argument that succeeded at the Supreme Court in 2024, when an earlier attempt to restrict the medication was rejected.

The FDA had separately requested the case be paused while it conducts its own safety review of mifepristone, commissioned by Health Secretary Robert F. Kennedy Jr. Reproductive health researchers have pushed back on the report that prompted the review, arguing it overstated the drug's risks and was not subject to peer review or published in a medical journal. The medication has been found safe and effective in numerous studies.

The Supreme Court's pause is temporary. Louisiana has been ordered to respond to the manufacturers' emergency requests by Thursday, after which the court will determine the next steps.

Source: HealthDay

Read this next

Judge Allows Abortion Pill, Mifepristone, To Continue Being Mailed for Now

THURSDAY, April 9, 2026 — U.S. District Judge David Joseph turned down Louisiana officials’ request to stop mail order delivery of the drug mifepristone nationwide...

America's Sexual Health Report Card Contains Some Surprises

THURSDAY, April 9, 2026 — Americans are becoming more comfortable with sexuality, with nearly all wanting and gaining pleasure from sex, a new study says. But they’re...

Federal Officials Investigate States That Require Abortion Coverage

WEDNESDAY, March 25, 2026 — Federal health officials say they are looking into 13 states that require certain health insurance plans to cover abortion. The U.S. Department...

More news resources

  • FDA Medwatch Drug Alerts
  • Daily MedNews
  • News for Health Professionals
  • New Drug Approvals
  • New Drug Applications
  • Drug Shortages
  • Clinical Trial Results
  • Generic Drug Approvals
  • Drugs.com Podcast

    • Subscribe to our newsletter

    Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

    Posted : 2026-05-05 09:26

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords